Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer

• Status: Withdrawn
• Trial end date: 2018-12-11
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate if proton beam therapy as part of chemoradiation results in a decrease in diffusion lung capacity of carbon monoxide (DLCO) compared to photon radiation therapy for esophageal carcinoma. A secondary objective is to determine effects on cardiac function, quality of life, and compare acute and late toxicities.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Treatments: Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Patient must be at least 18 years at the time of consent.

• Pathologically confirmed esophageal adenocarcinoma or squamous cell. carcinoma of the thoracic esophagus or esophagogastric junction.

• Patient's preliminary cancer stage, according to the AJCC 7th edition staging, must be cT1b-T4, N0-N3.

Exclusion Criteria:

• Patients with cervical esophageal carcinoma.

• Prior radiotherapy with fields overlapping the current esophageal cancer.

• Patients with cT1a disease.

• Patients with evidence of tracheoesophageal fistula must undergo bronchoscopy to exclude fistula.

• Patients with distant metastatic disease.